Carey Turnbull

Clinical-stage psychedelics biopharma company Ceruvia Lifesciences has dosed the first participant in its Phase 1 trial on NYPRG-101, aka BOL-148, an LSD non-hallucinogenic analog with a clinical and experimental administration history that dates back to the 1950s. "Having invested...

Clinical-stage biopharma company Ceruvia Lifesciences recently received FDA  approval for its Investigational New Drug (IND) application for a Phase 2 clinical trial to determine the efficacy and safety of proprietary synthetic psilocybin (SYNP-101) in treating obsessive-compulsive...